Paul Meller

The latest Innovation Scoreboard shows Europe is far short of its 2010 target of boosting R&D spending to 3 per cent of GDP.

Depending who you ask, the long-awaited and final ruling on the University of Wisconsin’s WARF patent is either a landmark decision or signifies nothing.

US genomics firm Myriad Genetics regains limited rights to BRCA1 breast cancer gene on final appeal.

The European Commission announces an overall community strategy to coordinate research, diagnosis and treatment of rare diseases.

Advanced grants for interdisciplinary research were awarded at the end of last week, completing the first wave of financing undertaken by the recently formed European Research Council (ERC).

The EU's flagships for industry/academic collaboration risk putting off researchers because the European Union won't fund more than 20 percent of overhead costs say research organisations.

The world’s five major patent offices are to join forces to banish duplication, make examination procedures more efficient and improve international patent rights.

The long-running row over software patenting has finally been referred to the highest appeals body of the European Patent Office.

Europe’s high-tech clusters are failing to reach their full potential. We need encourage more cooperation, says the Commission.

As stock markets turn their backs on the high-risk sectors, France Biotech’s annual survey reveals the depths to which investment has fallen.